Case Study

TargetCancer Foundation Successfully Engages And Empowers Rare Cancer Patients with Medrio

Source: Medrio
GettyImages-1332585814-oncology-patient-cancer

TargetCancer Foundation implemented Medrio’s remote consent function in their TCF-001 TRACK study, which has an objective to determine if rare tumors can benefit from matched molecular therapy. The study is remotely enrolling a total of 400 patients in the United States using electronic informed consent. Medrio’s eClinical solution provides significant benefits to TargetCancer Foundation including reduction of unnecessary delays, improved access to dispersed patients, privacy of review within the patient’s home environment, and increased patient and caregiver understanding.

Challenges

  • Patient access without physical or geographical constraints
  • Patient understanding of the molecular drivers of their rare cancer
  • Lack of real-time visibility into the consent process
VIEW THE CASE STUDY!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Leader